136 related articles for article (PubMed ID: 35085592)
1. A rational approach to assess off-target reactivity of a dual-signal integrator for T cell therapy.
Wang X; Wong LM; McElvain ME; Martire S; Lee WH; Li CZ; Fisher FA; Maheshwari RL; Wu ML; Imun MC; Murad R; Toledo Warshaviak D; Yin J; Kamb A; Xu H
Toxicol Appl Pharmacol; 2022 Feb; 437():115894. PubMed ID: 35085592
[TBL] [Abstract][Full Text] [Related]
2. Robust
Manry D; Bolanos K; DiAndreth B; Mock JY; Kamb A
Front Immunol; 2022; 13():826747. PubMed ID: 35359952
[TBL] [Abstract][Full Text] [Related]
3. A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo.
Sandberg ML; Wang X; Martin AD; Nampe DP; Gabrelow GB; Li CZ; McElvain ME; Lee WH; Shafaattalab S; Martire S; Fisher FA; Ando Y; Liu E; Ju D; Wong LM; Xu H; Kamb A
Sci Transl Med; 2022 Mar; 14(634):eabm0306. PubMed ID: 35235342
[TBL] [Abstract][Full Text] [Related]
4. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
5. HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity.
Bassan D; Weinberger L; Yi J; Kim T; Weist MR; Adams GB; Foord O; Chaim N; Tabak S; Bujanover N; Lopesco Y; Vucci K; Schnair C; Levy-Knafo L; Kendall RL; Calzone FJ; Sharbi-Yunger A
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38097342
[TBL] [Abstract][Full Text] [Related]
6. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Studies of the Off-Target Reactivity of AFP
Cai L; Caraballo Galva LD; Peng Y; Luo X; Zhu W; Yao Y; Ji Y; He Y
Front Immunol; 2020; 11():607. PubMed ID: 32395117
[TBL] [Abstract][Full Text] [Related]
8. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
[TBL] [Abstract][Full Text] [Related]
9. Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology.
Ebert LM; Yu W; Gargett T; Brown MP
Biochem Soc Trans; 2018 Apr; 46(2):391-401. PubMed ID: 29540509
[TBL] [Abstract][Full Text] [Related]
10. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.
Jensen MC; Riddell SR
Immunol Rev; 2014 Jan; 257(1):127-44. PubMed ID: 24329794
[TBL] [Abstract][Full Text] [Related]
11. Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Saito S; Nakazawa Y; Sueki A; Matsuda K; Tanaka M; Yanagisawa R; Maeda Y; Sato Y; Okabe S; Inukai T; Sugita K; Wilson MH; Rooney CM; Koike K
Cytotherapy; 2014 Sep; 16(9):1257-69. PubMed ID: 25108652
[TBL] [Abstract][Full Text] [Related]
12. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
13. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
15. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
16. A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration.
Sakemura R; Terakura S; Watanabe K; Julamanee J; Takagi E; Miyao K; Koyama D; Goto T; Hanajiri R; Nishida T; Murata M; Kiyoi H
Cancer Immunol Res; 2016 Aug; 4(8):658-68. PubMed ID: 27329987
[TBL] [Abstract][Full Text] [Related]
17. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
18. CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia.
Wu M; Zhang L; Zhang H; Ning J; Tu S; He Y; Li Y
Cytotherapy; 2019 Jun; 21(6):659-670. PubMed ID: 31031152
[TBL] [Abstract][Full Text] [Related]
19. Geometric parameters that affect the behavior of logic-gated CAR T cells.
Partin AC; Bruno R; Shafaattalab S; Vander Mause E; Winters A; Daris M; Gahrs C; Jette CA; DiAndreth B; Sandberg ML; Hamburger AE; Kamb A; Riley TP
Front Immunol; 2024; 15():1304765. PubMed ID: 38343543
[TBL] [Abstract][Full Text] [Related]
20. Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity.
Rushworth D; Jena B; Olivares S; Maiti S; Briggs N; Somanchi S; Dai J; Lee D; Cooper LJ
J Immunother; 2014 May; 37(4):204-13. PubMed ID: 24714354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
